Intra-Cellular Therapies, Inc.
ITCI US
ITCI USIntra-Cellular Therapies, Inc.
United States Composite68.80
Company Description
- Full Time Employees
- 610
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 430 East 29th Street New York NY United States 10016
- Business
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Company News
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
3 Biotech Stocks With Skyrocketing Potential: April 2024
3 Biotech Stocks With Skyrocketing Potential: April 2024
Analysts Are Bullish on Top Healthcare Stocks: Thermo Fisher (TMO), Intra-Cellular Therapies (ITCI)
Analysts Are Bullish on Top Healthcare Stocks: Thermo Fisher (TMO), Intra-Cellular Therapies (ITCI)
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
Analysts Conflicted on These Healthcare Names: Intra-Cellular Therapies (ITCI), Eli Lilly & Co (LLY) and Sanofi (OtherSNYNF)
Analysts Conflicted on These Healthcare Names: Intra-Cellular Therapies (ITCI), Eli Lilly & Co (LLY) and Sanofi (OtherSNYNF)